These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28270077)

  • 21. Synthesis and anticancer activity of novel rapamycin C-28 containing triazole moiety compounds.
    Huang Q; Xie L; Chen X; Yu H; Lv Y; Huang X; Ying J; Zheng C; Cheng Y; Huang J
    Arch Pharm (Weinheim); 2018 Nov; 351(11):e1800123. PubMed ID: 30357890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
    Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
    Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
    Czarnecka AM; Kornakiewicz A; Lian F; Szczylik C
    Future Oncol; 2015; 11(5):801-17. PubMed ID: 25757683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.
    Selka A; Doiron JA; Lyons P; Dastous S; Chiasson A; Cormier M; Turcotte S; Surette ME; Touaibia M
    Eur J Med Chem; 2019 Oct; 179():347-357. PubMed ID: 31260889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
    Wang X; Chen F; Gou S
    Bioorg Chem; 2020 Nov; 104():104234. PubMed ID: 32920359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma.
    Li F; Ma Z; Guan Z; Chen Y; Wu K; Guo P; Wang X; He D; Zeng J
    Int J Mol Sci; 2015 Apr; 16(4):8415-29. PubMed ID: 25884331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Involvement of p38-p53 signal pathway in resveratrol-induced apoptosis in MCF-7 cells].
    Zhang YH; Guo JG; Guo ZH; Xie SQ
    Yao Xue Xue Bao; 2011 Nov; 46(11):1332-7. PubMed ID: 22260024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
    Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
    Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
    Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
    PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
    Armstrong AJ; George DJ; Halabi S
    J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK.
    Zhang H; Chen GG; Zhang Z; Chun S; Leung BC; Lai PB
    Apoptosis; 2012 Apr; 17(4):325-34. PubMed ID: 22170404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
    Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
    Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
    Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
    Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.